Lanreotide

Description

Lanreotide

Also known as: Somatuline, Somatuline Depot

Lanreotide peptide shows a strong preference for binding to somatostatin receptors SST2 and SST5. It suppresses growth hormone (GH) secretion, lowers IGF-1 levels, and exerts antiproliferative effects on neuroendocrine tumor cells. The medication is available as a self-administered deep subcutaneous injection. It is approved by the FDA for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• A long-acting somatostatin analog closely related to octreotide, approved by the FDA for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.
• Approved by the FDA; classification based on established regulatory approval.
• Standard dosage ranges from 60 to 120 mg, administered via deep subcutaneous injection every four weeks.
• Investigated for use in acromegaly, neuroendocrine tumors, and managing hormonal activity.